Association of polymorphism rs1495741 of the NAT2 gene and the risk of developing inflammatory liver diseases under the influence of external factors
N. P. Peretolchina,
L. A. Stepanenko,
D. O. Kiselev,
A. V. Davidova,
S. D. Kravchenko,
I. V. Malov,
O. B. Ogarkov https://doi.org/10.25789/YMJ.2024.85.03
Abstract
Slow acetylation of substrate is associated with drug-induced liver damage and transformation of viral and alcohol hepatitis in cirrhosis. Increasing xenobiotic load is a significant factor in development of metabolic associated liver diseases. This interaction between genotype and environment should be studied to reveal disease pathogenesis. We analysed polymorphism rs1495741 genotypes in control group and in patients with cryptogenic liver cirrhosis and non-alcohol fatty liver disease to evaluate association of acetylation type with liver disease development. As part of the study, patients filled the questionnaire to assess xenobiotic load. The rs1495741 polymorphism was detected by real-time PCR. Significant differences were revealed in the criptogenic liver cirrhosis and non-alcoholic fatty liver disease groups in patients consuming fried and smoked foods (OR: 5,49 at p<0,05); in combination with older age (>55) the risk increases by 7.57 times (p<0,05). However, no association of the rs1495741 polymorphism with the development of liver diseases was identified.
About the Authors
N. P. Peretolchina
Irkutsk State Medical University
Russian Federation
Russian Federation
PERETOLCHINA Nadezhda P. – Junior Research Officer at the Research Institute of Biomedical Technologies
L. A. Stepanenko
Irkutsk State Medical University
Russian Federation
Russian Federation
STEPANENKO Liliya A. – PhD, Senior Research Officer at the Research Institute of Biomedical Technologies
D. O. Kiselev
Irkutsk State Medical University
Russian Federation
Russian Federation
KISELEV Dmitriy O. – Junior Research Officer at the Research Institute of Biomedical Technologies
A. V. Davidova
Irkutsk State Medical University
Russian Federation
Russian Federation
DAVYDOVA Anna V. – PhD, head of the Department of hospital therapy
S. D. Kravchenko
Irkutsk State Medical University
Russian Federation
Russian Federation
KRAVCHENKO Sofya D. – assistant lecturer of the Department of Faculty Therapy
I. V. Malov
Irkutsk State Medical University
Russian Federation
Russian Federation
MALOV Igor V. – MD, professor, head of the Department of Infectious Disease
O. B. Ogarkov
Scientific Centre for Family Health and Human Reproduction Problems
Russian Federation
Russian Federation
OGARKOV Oleg B. – MD, professor, Head of the Department of Epidemiology and Microbiology
References
1. Erdman V.V. [et al.] Analiz associacij farmakogeneticheskogo markera rs1208 gena NAT2 s vozrastom v trekh etnicheskih gruppah zhitelej respubliki Bashkortostan [Analysis of associations of the pharmacogenetic marker rs1208 of the NAT2 gene with age in three ethnic groups of residents of the Republic of Bashkortostan]. Genetika fundamental'naya osnova innovacij v medicine i selekcii. Materialy VIII nauchno-prakticheskoj konferencii s mezhdunarodnym uchastiem [Genetics is the fundamental basis of innovation in medicine and breeding. Materials of the VIII scientific and practical conference with international participation. Rostov-on-Don, Taganrog, 2019; 61-62. (In Russ.).]
2. Ogarkov O.B. [et al.] Metodika opredeleniya skorosti acetilirovaniya ksenobiotikov po taq SNP rs1495741 [A method to determine xenobiotic acetylation rate by taq SNP rs1495741]. Byulleten' eksperimental'noj biologii i mediciny [Bulletin of Experimental Biology and Medicine. 2022; 173(4):510-513.(In Russ.).] DOI: 10.1007/ s10517-022-05572-6
3. Yakupova T.G. [et al.] Osobennost' ekspressii genov pri toksicheskom povrezhdenii pecheni akrilamidom [The peculiarity of gene expression in toxic liver damage with acrylamide]. Medicina v Kuzbasse [Medicine in Kuzbass. 2023; 2:81-85. (In Russ.).] DOI: 10.24412/2687-0053-2023-281-85
4. Tsukanov V.V., Vasyutin A.V., Tonkikh Yu.L. Bremya cirroza pecheni v sovremennom mire [The Burden of Hepatic Cirrhosis in the Modern World]. Doktor.Ru [Doctor.Ru. 2021; 20(4):21–25. (In Russ.).] DOI: 10.31550/1727-2378-2021-204-21-25
5. García-Closas M. [et al.] A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenetics and Genomics. 2011; 21(4):231-236. DOI: 10.1097/ FPC.0b013e32833e1b54
6. Koszucka А. [et al.] Acrylamide in human diet, its metabolism, toxicity, inactivation and the associated European Union legal regulations in food industry. Critical Reviews in Food Science and Nutrition. 2020; 60(10):1677-1692. DOI: 0.1080/10408398.2019.1588222
7. Kobayashi M. [et al.] Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of stomach cancer: a hospital-based case-control study in Japan. Gastric Cancer. 2009; 12(4):198-205. DOI: 10.1007/s10120-0090523-x
8. Zang Y. [et al.] Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis. 2007; 28(8):1665-1671. DOI: 10.1093/carcin/bgm085
9. Hein D.W. N -acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opinion on Drug Metabolism & Toxicology. 2009; 5(4):353-366. DOI: 10.1517/17425250902877698
10. Wang P.-Y. [et al.] NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union Against Tuberculosis and Lung Disease. 2012; 16(5):589-595. DOI: 10.5588/ijtld.11.0377
11. Gaikovitch E.A. [et al.] Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. European Journal of Clinical Pharmacology. 2003; 59(4):303-312. DOI: 10.1007/s00228-003-0606-2
12. Yang K.-C. [et al.] Polymorphism of N-acetyltransferase 2 gene and the susceptibility to alcoholic liver cirrhosis: interaction with smoking. Alcoholism: Clinical and Experimental Research. 2011; 35(7):1204-1208. DOI: 10.1111/j.15300277.2011.01453.x
13. Huang Y.-S. [et al.] Polymorphism of the N -Acetyltransferase 2 gene, red meat intake, and the susceptibility of hepatocellular carcinoma. American Journal of Gastroenterology. 2003; 98(6):1417-1422. DOI: 10.1111/j.15720241.2003.07452.x
14. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2021.
15. Mirmiran P. [et al.] Relationship between Diet and Non-alcoholic Fatty Liver Disease: A Review Article. Iranian Journal of Public Health. 2017; 46(8):1007-1017.
16. Yabe Y. [et al.] Relationships of dietary habits and physical activity status with non-alcoholic fatty liver disease featuring advanced fibrosis. International Journal of Environmental Research and Public Health. 2021; 18(17):8918. DOI: 10.3390/ijerph18178918
17. González J.R. [et al.] SNPassoc: an R package to perform whole genome association studies. Bioinformatics. 2007; 23(5):654-655. DOI: 10.1093/bioinformatics/btm025
18. Younossi Z. [et al.] The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. Journal of Hepatology. 2018; 69(6):1365-1370. DOI: 10.1016/j. jhep.2018.08.013
19. Uhlen M. [et al.] Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419-1260419. DOI: 10.1126/science.1260419
Review
For citations:
Peretolchina N.P., Stepanenko L.A., Kiselev D.O., Davidova A.V., Kravchenko S.D., Malov I.V., Ogarkov O.B. Association of polymorphism rs1495741 of the NAT2 gene and the risk of developing inflammatory liver diseases under the influence of external factors. Yakut Medical Journal. 2024;(1):12-15. https://doi.org/10.25789/YMJ.2024.85.03
Views:
14
Email this article 